ADMA Biologics
ADMA
188 hedge funds and large institutions have $613M invested in ADMA Biologics in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 88 increasing their positions, 46 reducing their positions, and 15 closing their positions.
153% more call options, than puts
Call options by funds: $402K | Put options by funds: $159K
91% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 46
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
5% more funds holding
Funds holding: 179 → 188 (+9)
1.64% more ownership
Funds ownership: 74.46% → 76.1% (+1.6%)
0% more capital invested
Capital invested by funds: $611M → $613M (+$1.96M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$8.19M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.36M |
| 3 |
Morgan Stanley
New York
|
+$5.66M |
| 4 |
Millennium Management
New York
|
+$4.56M |
| 5 |
Goldman Sachs
New York
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$18.9M |
| 2 |
FAM
Fred Alger Management
New York
|
-$7.03M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$3.81M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.51M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.61M |
ADMA Hedge Fund Activity: Q3 2023 in Review
188 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2023, worth a combined $613M — up 0.32% from $611M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ADMA positions and 15 closed out — a net gain of 10 holders — while 88 added to existing stakes and 46 trimmed.
The largest buyer was Nuveen, adding an estimated $8.19M. The largest seller was Perceptive Advisors, cutting an estimated $18.9M.
- 188 institutional investors held ADMA Biologics (ADMA) as of Q3 2023, up from 179 in Q2 2023.
- Funds reported $613M of ADMA Biologics stock for Q3 2023, up 0.32% quarter-over-quarter.
- 25 funds opened new ADMA Biologics positions in Q3 2023 and 15 closed out, a net change of +10 holders.
- The largest ADMA Biologics buyer in Q3 2023 was Nuveen, an estimated $8.19M added.
- The largest ADMA Biologics seller in Q3 2023 was Perceptive Advisors, an estimated $18.9M sold.
Based on aggregated 13F filings for Q3 2023.